StudyFinder

A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants with Advanced Cancer

Status: Recruiting

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer.

I'm interested

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• advanced solid tumor
• restricted strenuous physical activity but can walk and able to carry light work e.g., light house work, office work
Exclusion Criteria:

• progressive or symptomatic brain metastases
• serious, uncontrolled medical disorder or active, uncontrolled infection
• history of significant hear disease
• history of another cancer within 3 years
• women who are pregnant or breast feeding
• contact study staff for additional exclusion criteria
Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), Advanced Solid Tumor, Endometrial Cancer, NSCLC, Ovarian Cancer

Study Contact: Boris Winterhoff - bwinterh@umn.edu
Principal Investigator: Boris Winterhoff
Phase: PHASE1
IRB Number: STUDY00014893
See this study on ClinicalTrials.gov

Back